Novozymes A/S
OTC:NVZMF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Novozymes A/S
OTC:NVZMF
|
DK |
|
B
|
Bridgestone Corp
DUS:BGT
|
JP |
|
Metal Powder Works Ltd
ASX:MPW
|
AU |
|
Lexaria Bioscience Corp
NASDAQ:LEXX
|
CA |
|
Relmada Therapeutics Inc
F:4E2
|
US |
|
Qube Holdings Ltd
ASX:QUB
|
AU |
|
P
|
Provident Financial Holdings Inc
NASDAQ:PROV
|
US |
|
Atlas Copco AB
LSE:0XXT
|
SE |
|
D
|
Diageo PLC
F:GUI
|
UK |
|
T
|
Trupanion Inc
F:TPW
|
US |
|
F
|
Fluor Corp
BMV:FLR
|
US |
|
Japan Real Estate Investment Corp
TSE:8952
|
JP |
|
A
|
Apollo Global Management Inc
LSE:0A72
|
US |
|
R
|
Regeneron Pharmaceuticals Inc
F:RGO
|
US |
|
S
|
Starwood Property Trust Inc
XBER:VSP
|
US |
|
A
|
Alamo Group Inc
XBER:AL3
|
US |
|
T
|
TE Connectivity Ltd
BMV:TELN
|
CH |
|
I
|
Intuit Inc
XHAM:ITU
|
US |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is NVZMF's stock price target?
Not Available
NVZMF does not have any price targets made by Wall Street professionals.
What is the Revenue forecast for Novozymes A/S?
Projected CAGR
-55%
Over the last 7 years, the compound annual growth rate for Revenue has been 3%. The projected CAGR for the next 2 years is -55%.
What is the Net Income forecast for Novozymes A/S?
Projected CAGR
-56%
Over the last 7 years, the compound annual growth rate for Net Income has been 0%. The projected CAGR for the next 2 years is -56%.